Vancomycin hydrochloride (manufactured in Copenhagen, Denmark)
Product Description
Xellia Pharmaceuticals ApS
-
Country/Region:Denmark
-
Founded:1903
-
On CPHI since:2015
-
Certificates:4
-
Employees:1000 - 4999
Company types
Primary activities
Categories
Specifications
Xellia Pharmaceuticals ApS
-
Country/Region:Denmark
-
Founded:1903
-
On CPHI since:2015
-
Certificates:4
-
Employees:1000 - 4999
Company types
Primary activities
More Products from Xellia Pharmaceuticals ApS (20)
-
Product Daptomycin
Daptomycin is a lipopeptide antibiotic active against gram-positive bacteria such as Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isol... -
Product Gramicidin
Gramicidin is a mixture of linear polypeptides active against a variety of gram-positive bacteria.
Indication: Ophthalmic solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacter... -
Product Polymyxin B sulfate
Polymyxin B sulfate is a mixture of sulfates of polypeptide antibiotics active against Pseudomonas aeruginosa and other gram-negative bacteria except the Proteus group.
Indication: Used in the treatment of acute urinary, meningeal or blood stream infections due to Pseu... -
Product Tobramycin sulfate
Tobramycin sulfate is the sulfate salt of tobramycin, an aminoglycoside antibiotic active against gram-negative bacteria including most Enterobacteriaceae, Pseudomonas aeruginosa and a few gram-positive bacteria such as Staphylococcus aureus.
Indication: ... -
Product Tyrothricin
Tyrothricin contains about 20% gramicidin and 80% tyrocidine and belongs to the family of polypeptide antibiotics. It is active against a variety of gram-positive bacteria, including Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus and bacteria causing diphtheria.
qq... -
Product Vancomycin hydrochloride (manufactured in Budapest, Hungary)
Vancomycin hydrochloride is a glycopeptide antibiotic active against a wide variety of gram-positive bacteria, most important being staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), but also active against diphtheroids, en... -
Product Vancomycin hydrochloride (manufactured in Taizhou, China)
Vancomycin hydrochloride is a glycopeptide antibiotic active against a wide variety of Gram-positive bacteria, most important being staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), but also active against diphtheroid... -
Product Colistimethate sodium dry-filled vials
Colistimethate sodium is a prodrug of colistin which is a mixture of polypeptide antibiotics active against gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.
Indication: Used in the treatment of patients with serious i... -
Product Colistimethate sodium lyophilized vials
Colistimethate sodium is a prodrug of colistin, which is a mixture of polypeptide antibiotics active against gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and especially Pseudomonas aeruginosa.
Indication:&nbs... -
Product Daptomycin vials
Daptomycin is a lipopeptide antibacterial agent active against gram-positive bacteria.
Indication: Used in the treatment of complicated skin and skin structure/soft-tissue infections caused by susceptible isolates of gram-positive bacteria such as Staphylococcus au... -
Product Daptomycin RT
Daptomycin is a lipopeptide antibacterial agent active against gram-positive bacteria.
Indication: Used in the treatment of complicated skin and skin structure/soft-tissue infections caused by susceptible isolates of gram-positive bacteria such as Staphylococcus aureus... -
Product Polymyxin B vials
Polymyxin B is a mixture of the sulfates of polypeptide antibiotics active against almost all gram-negative bacteria except the Proteus group.
Indication: Used in the treatment of patients with acute urinary, meningeal or blood-stream infections due to susceptible ...
Xellia Pharmaceuticals ApS resources (3)
-
Datasheet Xellia Corporate Introduction
Xellia Pharmaceuticals is a specialty pharmaceutical company developing,manufacturing and commercializing anti-infective treatments againstserious and often life-threatening bacterial and fungal infections. Xellia isa world-leading trusted supplier of several important established antiinfectivedrugs, comprising active pharmaceutical ingredients as well asfinished dosage forms, where the majority are injectable drug products.Headquartered in Copenhagen, Denmark and owned by Novo HoldingsA/S, Xellia Pharmaceuticals has more than 1800 employees globally.From state-of-the-art manufacturing sites in the U.S., China, Denmarkand Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticalsexcels within innovative product development to deliver high qualityproducts to its customers. -
Video Xellia Pharmaceuticals - We're your people
We are more than an API company. We are built on long standing relationships that have stood the test of time. Why? Because for 120 years we have been developing the anti-infectives the world needs. But we are evolving and in the future, we won't be known just for anti-infectives. Our ambition? To be the leading global supplier of APIs across many therapeutic areas. -
Brochure Xellia Pharmaceuticals Sustainability Report
Sustainability, the way we do everything else - honestly.
We make medicines that save lives. That's a responsibility we take seriously, in every direction — including the one that points toward the planet and the people we share it with.
Our 2025 Sustainability Report is out, and it tells a simple story: we're doing the work. Real numbers, real progress, real accountability — from our fermentation tanks in Copenhagen to our production lines in Budapest and Taizhou.
No greenwashing. No vague promises. Just a clear, honest look at where we stand and where we're headed — reviewed and signed off by our Executive Management team, because this matters enough to get right from the top.